Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker LGST, is a clinical-stage biopharmaceutical company focused on developing proprietary T-cell immunotherapies targeting infectious diseases and oncology indications. The company reached the public markets through a de-SPAC business combination and filed an S-1/A amendment with the SEC on July 23, 2024, under accession number 0001493152-24-028834, reflecting updated registration disclosures following its merger close. Operating in the biotechnology and life sciences sector, Tevogen Bio has positioned its platform around off-the-shelf, antigen-specific T-cell therapeutics. Investors and analysts tracking LGST's post-combination trajectory, pipeline milestones, and filing history can access the full dataset by signing up at SpacDesk.